FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078222208> ?p ?o ?g. }

• W2078222208 endingPage "516" @default.
• W2078222208 startingPage "507" @default.
• W2078222208 abstract "Abiraterone acetate is a small-molecule cytochrome P450 17A1 (CYP17A1) inhibitor that is active in castration-resistant prostate cancer. Our objective was to determine the impact of abiraterone with and without dexamethasone treatment on in vivo steroidogenesis. We treated 42 castrate, castration-resistant prostate cancer patients with continuous, daily abiraterone acetate and prospectively collected blood and urine before and during abiraterone treatment and after addition of dexamethasone 0.5 mg daily. Treatment with single-agent abiraterone acetate was associated with accumulation of steroids with mineralocorticoid properties upstream of CYP17A1. This resulted in side effects, including hypertension, hypokalemia, and fluid overload, in 38 of 42 patients that were generally treated effectively with eplerenone. Importantly, serum and urinary androgens were suppressed by more than 90% from baseline. Urinary metabolites of 17-hydroxypregnenolone and 17-hydroxyprogesterone downstream of 17α-hydroxylase remained unchanged. However, 3α5α-17-hydroxypregnanolone, which can be converted via the backdoor pathway toward 5α-dihydrotestosterone, increased significantly and correlated with levels of the major 5α-dihydrotestosterone metabolite androsterone. In contrast, urinary metabolites of 11-deoxycortisol and active glucocorticoids declined significantly. Addition of dexamethasone to abiraterone acetate significantly suppressed ACTH and endogenous steroids, including 3α5α-17-hydroxypregnanolone. CYP17A1 inhibition with abiraterone acetate is characterized by significant suppression of androgen and cortisol synthesis. The latter is associated with a rise in ACTH that causes raised mineralocorticoids, leading to side effects and incomplete 17α-hydroxylase inhibition. Concomitant inhibition of 17,20-lyase results in diversion of 17-hydroxyprogesterone metabolites toward androgen synthesis via the backdoor pathway. Addition of dexamethasone reverses toxicity and could further suppress androgens by preventing a rise in substrates of backdoor androgen synthesis." @default.
• W2078222208 created "2016-06-24" @default.
• W2078222208 creator A5000156180 @default.
• W2078222208 creator A5010324154 @default.
• W2078222208 creator A5013567386 @default.
• W2078222208 creator A5043630371 @default.
• W2078222208 creator A5046200187 @default.
• W2078222208 creator A5055037280 @default.
• W2078222208 creator A5055139623 @default.
• W2078222208 creator A5057689412 @default.
• W2078222208 creator A5062620682 @default.
• W2078222208 creator A5072378199 @default.
• W2078222208 creator A5091335645 @default.
• W2078222208 date "2012-02-01" @default.
• W2078222208 modified "2023-10-02" @default.
• W2078222208 title "Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer" @default.
• W2078222208 cites W1974657326 @default.
• W2078222208 cites W1985005329 @default.
• W2078222208 cites W1999560917 @default.
• W2078222208 cites W2001707407 @default.
• W2078222208 cites W2011956717 @default.
• W2078222208 cites W2018991487 @default.
• W2078222208 cites W2027081726 @default.
• W2078222208 cites W2037750383 @default.
• W2078222208 cites W2043103956 @default.
• W2078222208 cites W2051204558 @default.
• W2078222208 cites W2054854989 @default.
• W2078222208 cites W2064360128 @default.
• W2078222208 cites W2092172518 @default.
• W2078222208 cites W2093395170 @default.
• W2078222208 cites W2101606728 @default.
• W2078222208 cites W2110171529 @default.
• W2078222208 cites W2110534364 @default.
• W2078222208 cites W2113569308 @default.
• W2078222208 cites W2116458141 @default.
• W2078222208 cites W2117296712 @default.
• W2078222208 cites W2129876849 @default.
• W2078222208 cites W2139248078 @default.
• W2078222208 cites W2141569270 @default.
• W2078222208 cites W2150919715 @default.
• W2078222208 cites W2151317340 @default.
• W2078222208 cites W2155679349 @default.
• W2078222208 cites W2157312514 @default.
• W2078222208 cites W2167749314 @default.
• W2078222208 cites W2168011358 @default.
• W2078222208 cites W2170544517 @default.
• W2078222208 cites W2171041379 @default.
• W2078222208 doi "https://doi.org/10.1210/jc.2011-2189" @default.
• W2078222208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22170708" @default.
• W2078222208 hasPublicationYear "2012" @default.
• W2078222208 type Work @default.
• W2078222208 sameAs 2078222208 @default.
• W2078222208 citedByCount "226" @default.
• W2078222208 countsByYear W20782222082012 @default.
• W2078222208 countsByYear W20782222082013 @default.
• W2078222208 countsByYear W20782222082014 @default.
• W2078222208 countsByYear W20782222082015 @default.
• W2078222208 countsByYear W20782222082016 @default.
• W2078222208 countsByYear W20782222082017 @default.
• W2078222208 countsByYear W20782222082018 @default.
• W2078222208 countsByYear W20782222082019 @default.
• W2078222208 countsByYear W20782222082020 @default.
• W2078222208 countsByYear W20782222082021 @default.
• W2078222208 countsByYear W20782222082022 @default.
• W2078222208 countsByYear W20782222082023 @default.
• W2078222208 crossrefType "journal-article" @default.
• W2078222208 hasAuthorship W2078222208A5000156180 @default.
• W2078222208 hasAuthorship W2078222208A5010324154 @default.
• W2078222208 hasAuthorship W2078222208A5013567386 @default.
• W2078222208 hasAuthorship W2078222208A5043630371 @default.
• W2078222208 hasAuthorship W2078222208A5046200187 @default.
• W2078222208 hasAuthorship W2078222208A5055037280 @default.
• W2078222208 hasAuthorship W2078222208A5055139623 @default.
• W2078222208 hasAuthorship W2078222208A5057689412 @default.
• W2078222208 hasAuthorship W2078222208A5062620682 @default.
• W2078222208 hasAuthorship W2078222208A5072378199 @default.
• W2078222208 hasAuthorship W2078222208A5091335645 @default.
• W2078222208 hasBestOaLocation W20782222081 @default.
• W2078222208 hasConcept C121608353 @default.
• W2078222208 hasConcept C126322002 @default.
• W2078222208 hasConcept C134018914 @default.
• W2078222208 hasConcept C142716871 @default.
• W2078222208 hasConcept C181199279 @default.
• W2078222208 hasConcept C185592680 @default.
• W2078222208 hasConcept C2775832370 @default.
• W2078222208 hasConcept C2776992908 @default.
• W2078222208 hasConcept C2777899217 @default.
• W2078222208 hasConcept C2777911890 @default.
• W2078222208 hasConcept C2779881493 @default.
• W2078222208 hasConcept C2780192828 @default.
• W2078222208 hasConcept C2780401358 @default.
• W2078222208 hasConcept C55493867 @default.
• W2078222208 hasConcept C71315377 @default.
• W2078222208 hasConcept C71924100 @default.
• W2078222208 hasConcept C98274493 @default.
• W2078222208 hasConceptScore W2078222208C121608353 @default.
• W2078222208 hasConceptScore W2078222208C126322002 @default.
• W2078222208 hasConceptScore W2078222208C134018914 @default.

• next